Skip to main content
Erschienen in: Neurological Sciences 8/2021

21.05.2021 | COVID-19 | COVID-19 Zur Zeit gratis

Impact of COVID-19 on chronic migraine treated with erenumab: a case report

verfasst von: Alberto Grassini, Andrea Marcinnò, Fausto Roveta, Erica Gallo, Aurora Cermelli, Silvia Boschi, Elisa Rubino, Innocenzo Rainero

Erschienen in: Neurological Sciences | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Headache is a frequent symptom of the novel coronavirus 19 disease (COVID-19). To date, there are limited information on how COVID-19 affects migraine and its treatment.

Case description

A 47-year-old patient, suffering from chronic migraine and medication-overuse headache, in September 2020 started erenumab at 70 mg once monthly. Two months later, monthly migraine days decreased from 20 to 5. On the third month, the patient developed mild COVID-19 symptoms, experiencing extreme fatigue, hyposmia, and attention deficit, resulting positive for SARS-Cov-2 RNA. A significant increase in migraine attacks frequency was reported. Brain MRI and EEG were normal. Erenumab was increased to 140 mg/month, and attacks decreased to 3 monthly migraine days and remained stable. All the headaches experienced by our patient during the infection fulfilled the criteria of the migraine attacks, without tensive-like features.

Conclusion

We report the first case showing the effects of SARS-CoV-2 infection in a patient with chronic migraine and medication-overuse headache treated with erenumab. Our case description suggests that inflammatory processes induced by SARS-CoV-2 infection may increase the frequency of migraine attacks, probably through an activation of the trigeminovascular system. Whether treatment with CGRP receptor antagonist may influence COVID is still debated. Additional studies regarding anti-CGRP monoclonal antibodies in COVID-19 patients are warranted.
Literatur
1.
Zurück zum Zitat Lechien JR, Chiesa-Estomba CM, Place S, van Laethem Y, Cabaraux P, Mat Q, Huet K, Plzak J, Horoi M, Hans S, Rosaria Barillari M, Cammaroto G, Fakhry N, Martiny D, Ayad T, Jouffe L, Hopkins C, Saussez S, COVID‐19 Task Force of YO‐IFOS, Blecic S, de Siati DR, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Ris L, el Afia F, Harmegnies B, Distinguin L, Chekkoury-Idrissi Y, Circiu M, Lavigne P, Lopez Delgado I, Calvo-Henriquez C, Falanga C, Coppee F, le Bon SD, Rodriguez A, Dequanter D, Cornelis JP, Vergez S, Koenen L, Giuditta M, Molteni G, Tucciarone M, Radulesco T, Khalife M, Fourneau AF, Cherifi S, Manto M, Michel J, Radulesco T, Molteni G, Tucciarone M, Mannelli G, Cantarella G (2020) Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 288:335–344. https://doi.org/10.1111/joim.13089CrossRefPubMed Lechien JR, Chiesa-Estomba CM, Place S, van Laethem Y, Cabaraux P, Mat Q, Huet K, Plzak J, Horoi M, Hans S, Rosaria Barillari M, Cammaroto G, Fakhry N, Martiny D, Ayad T, Jouffe L, Hopkins C, Saussez S, COVID‐19 Task Force of YO‐IFOS, Blecic S, de Siati DR, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Ris L, el Afia F, Harmegnies B, Distinguin L, Chekkoury-Idrissi Y, Circiu M, Lavigne P, Lopez Delgado I, Calvo-Henriquez C, Falanga C, Coppee F, le Bon SD, Rodriguez A, Dequanter D, Cornelis JP, Vergez S, Koenen L, Giuditta M, Molteni G, Tucciarone M, Radulesco T, Khalife M, Fourneau AF, Cherifi S, Manto M, Michel J, Radulesco T, Molteni G, Tucciarone M, Mannelli G, Cantarella G (2020) Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 288:335–344. https://​doi.​org/​10.​1111/​joim.​13089CrossRefPubMed
7.
Zurück zum Zitat Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, Xiong L, Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q, Wu J, Xu L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X, Ye P, Zhu B, Wang L, Zhou W, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang W, Zhang L, Li L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55:102763. https://doi.org/10.1016/j.ebiom.2020.102763CrossRefPubMedPubMedCentral Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, Xiong L, Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q, Wu J, Xu L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X, Ye P, Zhu B, Wang L, Zhou W, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang W, Zhang L, Li L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55:102763. https://​doi.​org/​10.​1016/​j.​ebiom.​2020.​102763CrossRefPubMedPubMedCentral
Metadaten
Titel
Impact of COVID-19 on chronic migraine treated with erenumab: a case report
verfasst von
Alberto Grassini
Andrea Marcinnò
Fausto Roveta
Erica Gallo
Aurora Cermelli
Silvia Boschi
Elisa Rubino
Innocenzo Rainero
Publikationsdatum
21.05.2021
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Neurological Sciences / Ausgabe 8/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05329-5

Weitere Artikel der Ausgabe 8/2021

Neurological Sciences 8/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.